GWAS and polygenic risk score of severe COVID-19 in Eastern Europe.

IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Frontiers in Medicine Pub Date : 2024-09-19 eCollection Date: 2024-01-01 DOI:10.3389/fmed.2024.1409714
Elena Kovalenko, Layal Shaheen, Ekaterina Vergasova, Alexey Kamelin, Valerya Rubinova, Dmitry Kharitonov, Anna Kim, Nikolay Plotnikov, Artem Elmuratov, Natalia Borovkova, Maya Storozheva, Sergey Solonin, Irina Gilyazova, Petr Mironov, Elza Khusnutdinova, Sergey Petrikov, Anna Ilinskaya, Valery Ilinsky, Alexander Rakitko
{"title":"GWAS and polygenic risk score of severe COVID-19 in Eastern Europe.","authors":"Elena Kovalenko, Layal Shaheen, Ekaterina Vergasova, Alexey Kamelin, Valerya Rubinova, Dmitry Kharitonov, Anna Kim, Nikolay Plotnikov, Artem Elmuratov, Natalia Borovkova, Maya Storozheva, Sergey Solonin, Irina Gilyazova, Petr Mironov, Elza Khusnutdinova, Sergey Petrikov, Anna Ilinskaya, Valery Ilinsky, Alexander Rakitko","doi":"10.3389/fmed.2024.1409714","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 disease has infected more than 772 million people, leading to 7 million deaths. Although the severe course of COVID-19 can be prevented using appropriate treatments, effective interventions require a thorough research of the genetic factors involved in its pathogenesis.</p><p><strong>Methods: </strong>We conducted a genome-wide association study (GWAS) on 7,124 individuals (comprising 6,400 controls who had mild to moderate COVID-19 and 724 cases with severe COVID-19). The inclusion criteria were acute respiratory distress syndrome (ARDS), acute respiratory failure (ARF) requiring respiratory support, or CT scans indicative of severe COVID-19 infection without any competing diseases. We also developed a polygenic risk score (PRS) model to identify individuals at high risk.</p><p><strong>Results: </strong>We identified two genome-wide significant loci (<i>P</i>-value <5 × 10<sup>-8</sup>) and one locus with approximately genome-wide significance (<i>P</i>-value = 5.92 × 10<sup>-8</sup>-6.15 × 10<sup>-8</sup>). The most genome-wide significant variants were located in the <i>leucine zipper transcription factor like 1</i> (<i>LZTFL1</i>) gene, which has been highlighted in several previous GWAS studies. Our PRS model results indicated that individuals in the top 10% group of the PRS had twice the risk of severe course of the disease compared to those at median risk [odds ratio = 2.18 (1.66, 2.86), <i>P</i>-value = 8.9 × 10<sup>-9</sup>].</p><p><strong>Conclusion: </strong>We conducted one of the largest studies to date on the genetics of severe COVID-19 in an Eastern European cohort. Our results are consistent with previous research and will guide further epidemiologic studies on host genetics, as well as for the development of targeted treatments.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446758/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2024.1409714","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: COVID-19 disease has infected more than 772 million people, leading to 7 million deaths. Although the severe course of COVID-19 can be prevented using appropriate treatments, effective interventions require a thorough research of the genetic factors involved in its pathogenesis.

Methods: We conducted a genome-wide association study (GWAS) on 7,124 individuals (comprising 6,400 controls who had mild to moderate COVID-19 and 724 cases with severe COVID-19). The inclusion criteria were acute respiratory distress syndrome (ARDS), acute respiratory failure (ARF) requiring respiratory support, or CT scans indicative of severe COVID-19 infection without any competing diseases. We also developed a polygenic risk score (PRS) model to identify individuals at high risk.

Results: We identified two genome-wide significant loci (P-value <5 × 10-8) and one locus with approximately genome-wide significance (P-value = 5.92 × 10-8-6.15 × 10-8). The most genome-wide significant variants were located in the leucine zipper transcription factor like 1 (LZTFL1) gene, which has been highlighted in several previous GWAS studies. Our PRS model results indicated that individuals in the top 10% group of the PRS had twice the risk of severe course of the disease compared to those at median risk [odds ratio = 2.18 (1.66, 2.86), P-value = 8.9 × 10-9].

Conclusion: We conducted one of the largest studies to date on the genetics of severe COVID-19 in an Eastern European cohort. Our results are consistent with previous research and will guide further epidemiologic studies on host genetics, as well as for the development of targeted treatments.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
东欧严重 COVID-19 的基因组分析和多基因风险评分。
背景:COVID-19疾病已感染7.72亿人,导致700万人死亡。虽然通过适当的治疗可以预防 COVID-19 的严重病程,但有效的干预措施需要对其发病机制中的遗传因素进行深入研究:我们对 7124 人进行了全基因组关联研究(GWAS)(包括 6400 名患有轻度至中度 COVID-19 的对照者和 724 名患有重度 COVID-19 的病例)。纳入标准是急性呼吸窘迫综合征(ARDS)、需要呼吸支持的急性呼吸衰竭(ARF),或 CT 扫描显示感染了严重的 COVID-19,但没有任何其他疾病。我们还建立了一个多基因风险评分(PRS)模型,以确定高风险个体:我们发现了两个全基因组显著位点(P 值 -8)和一个近似全基因组显著位点(P 值 = 5.92 × 10-8-6.15 × 10-8)。最具有全基因组意义的变异位于亮氨酸拉链转录因子 1(LZTFL1)基因中,该基因在之前的几项 GWAS 研究中得到了强调。我们的PRS模型结果表明,与中位风险的人相比,PRS前10%组的人患严重病程的风险是后者的两倍[几率比=2.18(1.66,2.86),P值=8.9×10-9]:我们在东欧人群中开展了迄今为止最大规模的重症 COVID-19 遗传学研究之一。我们的研究结果与之前的研究结果一致,并将指导有关宿主遗传学的进一步流行病学研究,以及开发有针对性的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Medicine
Frontiers in Medicine Medicine-General Medicine
CiteScore
5.10
自引率
5.10%
发文量
3710
审稿时长
12 weeks
期刊介绍: Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world
期刊最新文献
Adult diffuse hepatic hemangiomatosis lesion occupying the entire abdominal and pelvic cavities: a case report. Applications of optical coherence tomography angiography in glaucoma: current status and future directions. Case report: A suspected case of chronic pulmonary sparganosis characterized by migrating cavities and tunnel sign. Comparing the effectiveness and safety of videolaryngoscopy and direct laryngoscopy for endotracheal intubation in the paediatric emergency department: a systematic review and meta-analysis. Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis - a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1